Sergio Traversa, Relmada Therapeutics CEO
Relmada makes 'critical changes' to PhIII trial to try and save depression drug
Relmada Therapeutics is making changes to its Phase III study of its lead drug for major depressive disorder, in an attempt to avoid problems with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
